

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:07:59 ON 26 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 09:08:50 ON 26 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 DEC 2006 HIGHEST RN 916309-42-7

DICTIONARY FILE UPDATES: 25 DEC 2006 HIGHEST RN 916309-42-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10522967.str

Connecting via Winsock to STN

Welcome to STN International! Enter x:x



LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS	23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS	28	DEC 18	CA/CAplus patent kind codes updated
NEWS	29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS	30	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available



```

chain nodes :
30 31 32 33 34 35 36 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27
chain bonds :
1-7 2-37 3-38 5-36 6-35 8-34 9-13 10-32 11-33 17-22 26-30 27-31
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17
14-15 14-18 15-16 15-21 16-17 18-19 19-20 20-21 22-23 22-27 23-24 24-25
25-26 26-27
exact/norm bonds :
1-7 2-37 3-38 5-36 6-35 8-34 9-13 10-32 11-33 13-14 13-17 14-15 14-18
15-16 15-21 16-17 17-22 18-19 19-20 20-21 22-23 22-27 23-24 24-25 25-26
26-27 26-30 27-31
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 13 : 22 :

```

G1:N,CH

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 30:CLASS
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS


```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 N,CH

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 09:09:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 09:09:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 249 TO ITERATE

100.0% PROCESSED 249 ITERATIONS 66 ANSWERS
SEARCH TIME: 00.00.01

L3 66 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	166.94	167.36

FILE 'CAPLUS' ENTERED AT 09:09:26 ON 26 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 26 Dec 2006 VOL 146 ISS 1
FILE LAST UPDATED: 25 Dec 2006 (20061225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:120853 CAPLUS

DOCUMENT NUMBER: 140:163875

TITLE: Preparation of imidazopyridines as inhibitors of the
transforming growth factor-beta (TGF- β)
signalling pathway

INVENTOR(S): Dodic, Nerina; Gellibert, Francoise Jeanne

PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013138	A2	20040212	WO 2003-EP8390	20030729
WO 2004013138	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003255323	A1	20040223	AU 2003-255323	20030729
EP 1543003	A2	20050622	EP 2003-766355	20030729
EP 1543003	B1	20060517		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005537291	T	20051208	JP 2004-525375	20030729
AT 326467	T	20060615	AT 2003-766355	20030729
ES 2259419	T3	20061001	ES 2003-3766355	20030729
US 2005234029	A1	20051020	US 2005-522967	20050131
PRIORITY APPLN. INFO.:			GB 2002-17783	A 20020731
			WO 2003-EP8390	W 20030729
OTHER SOURCE(S):	MARPAT 140:163875			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein X = CH or N; R1 = H, alk(en/yn)yl, perfluoro/alkoxy, halo, CN, perfluoroalkyl, NH2 and derivs., (CH2)nNH2 and

derivs., CONH2 and derivs., SO2H and derivs., SO2NH2 and derivs., etc.; R2 = H, alkyl, halo, CN, perfluoroalkyl; R3 = H, halo; R4 = H, halo, alkyl, NH2 and derivs.; n = 1-4] were prepared as inhibitors of the transforming growth factor-beta (TGF- β) signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF- β type I or activin-like kinase-5 (ALK-5) receptor for treatment and prevention of a disease state mediated by this pathway. For example, II was prepared in 3 steps by reaction of 2-bromo-4-methylpyridine with 6-methylpicolinic acid Me ester, cyclocondensation of ethanone with 2-aminopyridine, and Pd-cross coupling of III with 4-(methanesulfonyl)phenylboronic acid. II showed an ALK5 receptor modulator activity of 11 nM in an ALK5 fluorescence polarization assay and TGF- β cellular activity of 125 nM in a cellular transcriptional assay. Thus, I are useful for treating or preventing a disease or condition mediated by ALK-5 inhibition, in particular kidney fibrosis.

IT 656239-73-5P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-74-6P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-75-7P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-trifluoromethoxyphenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-76-8P, 3-[2-(4-Cyanophenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-77-9P, 3-[2-(4-(Methanesulfonyl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-78-0P, 3-[2-(4-(Methanesulfonyl)phenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-79-1P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-(4-(methylsulfonyl)phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-80-4P, 3-[2-(4-(Acetyl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-81-5P, 3-[2-(4-(Methylcarbonylamino)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-82-6P, 3-[2-(4-(Methylcarbonylamino)phenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-83-7P, 2-(3-Chlorophenyl)-3-[2-(4-[(methanesulfonyl)amino]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-84-8P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-aminophenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-85-9P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-[(trifluoromethylsulfonyl)amino]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-86-0P, 3-[2-(4-(Morpholin-4-yl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-87-1P, 3-[2-(4-(4-Methylpiperazin-1-yl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-88-2P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-89-3P, 3-[2-(4-(Morpholin-4-yl)methyl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-90-6P, 2-(3-Chloro-4-fluorophenyl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-91-7P, 2-(3,4-Difluorophenyl)-3-[2-(4-[(pyrrolidin-1-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-92-8P, 2-(3,4-Difluorophenyl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-93-9P, 6-Chloro-2-(6-methylpyridin-2-yl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-94-0P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-95-1P, 6-Chloro-2-(6-methylpyridin-2-yl)-3-[2-(4-[(pyrrolidin-1-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-96-2P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-(4-[(morpholin-4-yl)methyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656239-97-3P 656239-98-4P, 3-[2-(4-[(Tetrahydropyran-4-yl)amino]carbonyl)phenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-99-5P, 3-[2-(4-[(Tetrahydropyran-4-yl)amino]carbonyl)phenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-00-5P, 2-(3-Chlorophenyl)-3-[2-(4-[(tetrahydropyran-4-yl)amino]carbonyl)phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656240-01-6P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-[(morpholin-4-yl)carbonyl]phenyl)pyridin-4-yl]imidazo[1,2-a]pyridine 656240-02-7P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-[(3-


methoxypropylamino)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-03-8P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-
 [(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-04-9P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(1-
 ethylpiperazin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-05-0P, 2-(6-Fluoropyridin-2-yl)-3-[2-[4-[(morpholin-4-
 yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-06-1P, 2-(Pyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-
 yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-07-2P
 , 2-(6-Methylpyridin-2-yl)-3-[2-[4-[2-(dimethylamino)ethoxy]phenyl]pyridin-
 4-yl]imidazo[1,2-a]pyridine 656240-08-3P, 2-(3-Chlorophenyl)-3-
 [2-[4-[2-(dimethylamino)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-09-4P, 2-(3-Chlorophenyl)-3-[2-[4-[2-(pyrrolidin-1-
 yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-10-7P
 , 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-
 yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-11-8P
 , 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(morpholin-4-
 yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-12-9P
 , 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-1-
 yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-13-0P
 , 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-4-
 yl)methyloxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-14-1P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(1-methylimidazol-
 4-yl)methyloxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-15-2P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-
 [[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-16-3P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-
 [[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-17-4P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-(morpholin-4-
 yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-18-5P,
 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-
 yl]imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(inhibitor of TGF- β signaling pathway; preparation of imidazopyridines
 as inhibitors of transforming growth factor-beta (TGF- β) signaling
 pathway)


RN 656239-73-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(2-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-74-6 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(6-methyl-2-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-75-7 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(trifluoromethoxy)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-76-8 CAPLUS
 CN Benzonitrile, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-77-9 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-78-0 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-79-1 CAPLUS
 CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-80-4 CAPLUS

CN Ethanone, 1-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-81-5 CAPLUS

CN Acetamide, N-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-82-6 CAPLUS

CN Acetamide, N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-83-7 CAPLUS

CN Methanesulfonamide, N-[4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-84-8 CAPLUS

CN Benzenamine, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-85-9 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-86-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-87-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-88-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-89-3 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-90-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-91-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3,4-difluorophenyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-92-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3,4-difluorophenyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-93-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-94-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-95-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-96-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656239-97-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 656239-98-4 CAPLUS

CN Benzamide, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656239-99-5 CAPLUS

CN Benzamide, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656240-00-5 CAPLUS

CN Benzamide, 4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656240-01-6 CAPLUS

CN Morpholine, 4-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-02-7 CAPLUS

CN Benzamide, N-(3-methoxypropyl)-4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-03-8 CAPLUS

CN Morpholine, 4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-04-9 CAPLUS

CN Piperazine, 1-ethyl-4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-05-0 CAPLUS

CN Morpholine, 4-[4-[4-[2-(6-fluoro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-06-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-07-2 CAPLUS


CN Ethanamine, N,N-dimethyl-2-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-08-3 CAPLUS
 CN Ethanamine, 2-[4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 656240-09-4 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(3-chlorophenyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-10-7 CAPLUS
 CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-11-8 CAPLUS
 CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-12-9 CAPLUS
 CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-13-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656240-14-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656240-15-2 CAPLUS

CN Acetamide, 2-[4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-16-3 CAPLUS

CN Acetamide, 2-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-17-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-18-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656239-54-2P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-55-3P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-56-4P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(3-chloro-4-fluorophenyl)imidazo[1,2-a]pyridine 656239-57-5P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(3,4-difluorophenyl)imidazo[1,2-a]pyridine 656239-58-6P, 6-Chloro-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-59-7P, 7-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-60-0P, 8-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-61-1P, 3-[2-[4-(Carboxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-62-2P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-63-3P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-64-4P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(3-chlorophenyl)imidazo[1,2-a]pyridine 656239-65-5P, 8-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-66-6P, 7-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-67-7P, 3-[2-(4-Bromophenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-68-8P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-69-9P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-71-3P, 7-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-


alpyridine 656239-72-4P, 8-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazopyridines as inhibitors of transforming growth factor-beta (TGF- β) signaling pathway)


RN 656239-54-2 CAPLUS

CN Benzaldehyde, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-55-3 CAPLUS

CN Benzaldehyde, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-56-4 CAPLUS

CN Benzaldehyde, 4-[4-[2-(3-chloro-4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-57-5 CAPLUS

CN Benzaldehyde, 4-[4-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-58-6 CAPLUS

CN Benzaldehyde, 4-[4-[6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-59-7 CAPLUS

CN Benzaldehyde, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-60-0 CAPLUS

CN Benzaldehyde, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-61-1 CAPLUS

CN Benzoic acid, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-62-2 CAPLUS

CN Phenol, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-
(9CI) (CA INDEX NAME)




RN 656239-63-3 CAPLUS

CN Phenol, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-
pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-64-4 CAPLUS

CN Phenol, 4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-
(9CI) (CA INDEX NAME)




RN 656239-65-5 CAPLUS

CN Phenol, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-
2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-66-6 CAPLUS

CN Phenol, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-67-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-bromophenyl)-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-68-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-69-9 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-71-3 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-7-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 656239-72-4 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-8-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:120851 CAPLUS
 DOCUMENT NUMBER: 140:181331
 TITLE: Preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders
 INVENTOR(S): Dodic, Nerina; Gellibert, Francoise Jeanne
 PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
 SOURCE: PCT Int. Appl., 119 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013135	A1	20040212	WO 2003-EP8496	20030729
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003260345	A1	20040223	AU 2003-260345	20030729
EP 1539748	A1	20050615	EP 2003-766385	20030729
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005539000	T	20051222	JP 2004-525405	20030729
US 2005245520	A1	20051103	US 2005-522969	20050131
PRIORITY APPLN. INFO.:			GB 2002-17751	A 20020731

OTHER SOURCE(S):
GI

MARPAT 140:181331



I



II

AB This invention relates to novel 2-phenylpyridin-4-yl heterocycles (shown as I; variables defined below; e.g. II) that are inhibitors of the transforming growth factor, ('TGF')- β signaling pathway, in particular, the phosphorylation of Smad-2 or Smad-3 by the TGF- β type I or activin-like kinase ('ALK')-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway, e.g. fibrosis (no data). All examples of I show ALK-5 receptor modulator activity (having IC₅₀ values at 0.4-275 nM) and TGF- β cellular activity (having IC₅₀ values at 0.001-10 μ M). 4-[4-[4-[2-tert-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]pyridin-2-yl]phenyl]morpholine showed an ALK-5 receptor modulator activity of 34 nM and TGF- β cellular activity of 183 nM. N-(tetrahydropyran-4-yl)-4-[4-[2-isopropyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]pyridin-2-yl]benzamide showed an ALK-5 receptor modulator activity of 25 nM and TGF- β cellular activity of <14 nM. Although the methods of preparation are not claimed, >150 example preps. of I and .apprx.130 example preps. of intermediates are included. For example, II was prepared in 37% yield by reacting 4-[4-[3-(6-methylpyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]pyridin-2-yl]phenol and NaH in DMF with 1-methyl-4-hydroxymethylimidazole followed by removal of the trityl group using HCl in MeOH; details are also given for preparation of the reactants. For I: A is furan, dioxolane, thiophene, pyrrole, imidazole, pyrrolidine, pyran, pyridine, pyrimidine, morpholine, piperidine, oxazole, isoxazole, oxazoline, oxazolidine, thiazole, isothiazole, thiadiazole, benzofuran, indole, isoindole, indazole, imidazopyridine, quinazoline, quinoline, isoquinoline, pyrazole or triazole; X is N or CH; R1 is H, C1-6alkyl, C1-6alkenyl, C1-6alkoxy, halo, cyano, perfluoro C1-6alkyl, perfluoroC1-6alkoxy, -NR5R6, -(CH2)nNR5R6, -O(CH2)nOR7, -O(CH2)n-Het, -O(CH2)nNR5R6, -CONR5R6, -CO(CH2)nNR5R6, -SO2R7, -SO2NR5R6, -NR5SO2R7, -NR5COR7, -O(CH2)nCONR5R6, -NR5CO(CH2)nNR5R6 or -C(O)R7; R2 is H, C1-6alkyl, halo, cyano or perfluoroC1-6alkyl; R3 is H or halo; R4 is H,

halo, Ph, C1-6alkyl or -NR5R6; addnl. details including provisos are given in the claims.


IT 656239-82-6P, 3-[2-[4-(Acetylamino)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-84-8P, 2-(6-Methylpyridin-2-yl)-3-[2-(4-aminophenyl)pyridin-4-yl]imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)


RN 656239-82-6 CAPLUS

CN Acetamide, N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 656239-84-8 CAPLUS

CN Benzenamine, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT 656239-73-5P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-74-6P, 3-[2-(4-Methoxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-75-7P, 3-[2-[4-(Trifluoromethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-76-8P, 3-[2-(4-Cyanophenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-77-9P, 3-[2-[4-(Methylsulfonyl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-78-0P, 3-[2-[4-(Methylsulfonyl)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-79-1P, 8-Methyl-3-[2-[4-(methylsulfonyl)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-80-4P, 3-[2-(4-Acetylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-81-5P, 3-[2-[4-(Acetylamino)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-83-7P, 3-[2-[4-[(Methylsulfonyl)amino]phenyl]pyridin-4-yl]-2-(3-chlorophenyl)imidazo[1,2-a]pyridine 656239-85-9P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(trifluoromethylsulfonyl)amino]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-86-0P, 3-[2-[4-(Morpholin-4-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-87-1P, 3-[2-[4-(4-Methylpiperazin-1-yl)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-88-2P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(morpholin-4-yl)methyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656239-89-3P, 3-[2-[4-[(Morpholin-4-yl)methyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-90-6P, 3-[2-[4-[(Morpholin-4-


yl)methyl]phenyl]pyridin-4-yl]-2-(3-chloro-4-fluorophenyl)imidazo[1,2-
 a]pyridine 656239-91-7P, 3-[2-[4-[(Pyrrolidin-1-
 yl)methyl]phenyl]pyridin-4-yl]-2-(3,4-difluorophenyl)imidazo[1,2-
 a]pyridine 656239-92-8P, 3-[2-[4-[(Morpholin-4-
 yl)methyl]phenyl]pyridin-4-yl]-2-(3,4-difluorophenyl)imidazo[1,2-
 a]pyridine 656239-93-9P, 6-Chloro-3-[2-[4-[(morpholin-4-
 yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656239-94-0P, 7-Methyl-3-[2-[4-[(morpholin-4-
 yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656239-95-1P, 6-Chloro-3-[2-[4-[(pyrrolidin-1-
 yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656239-96-2P, 8-Methyl-3-[2-[4-[(morpholin-4-
 yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656239-98-4P, 3-[2-[4-[[[Tetrahydropyran-4-
 yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-
 a]pyridine 656239-99-5P, 3-[2-[4-[[[Tetrahydropyran-4-
 yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656240-00-5P, 3-[2-[4-[[[Tetrahydropyran-4-
 yl)amino]carbonyl]phenyl]pyridin-4-yl]-2-(3-chlorophenyl)imidazo[1,2-
 a]pyridine 656240-01-6P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-
 [(morpholin-4-yl)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-02-7P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[(3-
 methoxypropylamino)carbonyl]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-03-8P, 8-Methyl-3-[2-[4-[(morpholin-4-
 yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656240-04-9P, 8-Methyl-3-[2-[4-[(4-ethylpiperazin-1-
 yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-
 a]pyridine 656240-05-0P, 3-[2-[4-[(Morpholin-4-
 yl)carbonyl]phenyl]pyridin-4-yl]-2-(6-fluoropyridin-2-yl)imidazo[1,2-
 a]pyridine 656240-06-1P, 2-(Pyridin-2-yl)-3-[2-[4-[2-(pyrrolidin-
 1-yl)ethoxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-08-3P, 3-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]pyridin-4-
 yl]-2-(3-chlorophenyl)imidazo[1,2-a]pyridine 656240-09-4P,
 3-[2-[4-[2-(Pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]-2-(3-
 chlorophenyl)imidazo[1,2-a]pyridine 656240-13-0P,
 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-[[[1-methylimidazol-4-
 yl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-14-1P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-[[[1-methylimidazol-
 4-yl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-15-2P, 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-
 [[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-16-3P, 8-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-
 [[(aminocarbonyl)methyl]oxy]phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine
 656240-17-4P, 2-(6-Methylpyridin-2-yl)-3-[2-[4-(morpholin-4-
 yl)phenyl]pyridin-4-yl]imidazo[1,2-a]pyridine 656240-18-5P,
 7-Methyl-2-(6-methylpyridin-2-yl)-3-[2-[4-(morpholin-4-yl)phenyl]pyridin-4-
 yl]imidazo[1,2-a]pyridine 657399-23-0P, 8-Methyl-3-[2-[4-
 [(pyrrolidin-1-yl)methyl]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-
 yl)imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of 2-phenylpyridin-4-yl heterocycles as
 selective activin-like kinase-5 inhibitors useful against fibrosis and
 other disorders)


RN 656239-73-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(2-
 pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-74-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-methoxyphenyl)-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-75-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(trifluoromethoxy)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-76-8 CAPLUS

CN Benzonitrile, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-77-9 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-78-0 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-79-1 CAPLUS
 CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(methylsulfonyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-80-4 CAPLUS
 CN Ethanone, 1-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 656239-81-5 CAPLUS
 CN Acetamide, N-[4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-83-7 CAPLUS
 CN Methanesulfonamide, N-[4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-85-9 CAPLUS

CN Methanesulfonamide, 1,1,1-trifluoro-N-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenyl]- (9CI) (CA INDEX NAME)




RN 656239-86-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-87-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-methyl-1-piperazinyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-88-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-89-3 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656239-90-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3-chloro-4-fluorophenyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-91-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3,4-difluorophenyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-92-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(3,4-difluorophenyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-93-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-94-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-95-1 CAPLUS

CN Imidazo[1,2-a]pyridine, 6-chloro-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-96-2 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-98-4 CAPLUS

CN Benzamide, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656239-99-5 CAPLUS

CN Benzamide, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656240-00-5 CAPLUS

CN Benzamide, 4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]-N-(tetrahydro-2H-pyran-4-yl)- (9CI) (CA INDEX NAME)




RN 656240-01-6 CAPLUS

CN Morpholine, 4-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-02-7 CAPLUS

CN Benzamide, N-(3-methoxypropyl)-4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-03-8 CAPLUS

CN Morpholine, 4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-04-9 CAPLUS

CN Piperazine, 1-ethyl-4-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-05-0 CAPLUS


CN Morpholine, 4-[4-[4-[2-(6-fluoro-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 656240-06-1 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-08-3 CAPLUS
 CN Ethanamine, 2-[4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 656240-09-4 CAPLUS
 CN Imidazo[1,2-a]pyridine, 2-(3-chlorophenyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-13-0 CAPLUS
 CN Imidazo[1,2-a]pyridine, 7-methyl-3-[2-[4-[(1-methyl-1H-imidazol-4-yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656240-14-1 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-[(1-methyl-1H-imidazol-4-

yl)methoxy]phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 656240-15-2 CAPLUS

CN Acetamide, 2-[4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-16-3 CAPLUS

CN Acetamide, 2-[4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-17-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656240-18-5 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(4-morpholinyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 657399-23-0 CAPLUS

CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-(1-pyrrolidinylmethyl)phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




IT 656240-07-2P, 3-[2-[4-[2-(Dimethylamino)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-10-7P, 7-Methyl-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-11-8P, 7-Methyl-3-[2-[4-[2-(morpholin-4-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656240-12-9P, 8-Methyl-3-[2-[4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)


RN 656240-07-2 CAPLUS

CN Ethanamine, N,N-dimethyl-2-[4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 656240-10-7 CAPLUS


CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-11-8 CAPLUS
 CN Imidazo[1,2-a]pyridine, 7-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 656240-12-9 CAPLUS
 CN Imidazo[1,2-a]pyridine, 8-methyl-2-(6-methyl-2-pyridinyl)-3-[2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)




IT 656239-54-2P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-55-3P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-56-4P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(3-chloro-4-fluorophenyl)imidazo[1,2-a]pyridine 656239-57-5P, 3-[2-(4-Formylphenyl)pyridin-4-yl]-2-(3,4-difluorophenyl)imidazo[1,2-a]pyridine 656239-58-6P, 6-Chloro-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-59-7P, 7-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-60-0P, 8-Methyl-3-[2-(4-formylphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-61-1P, 3-[2-(4-Carboxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-62-2P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-63-3P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-64-4P, 3-[2-(4-Hydroxyphenyl)pyridin-4-yl]-2-(3-chlorophenyl)imidazo[1,2-a]pyridine 656239-65-5P, 8-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-66-6P, 7-Methyl-3-[2-(4-hydroxyphenyl)pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-67-7P, 3-[2-(4-Bromophenyl)pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-68-8P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(pyridin-2-yl)imidazo[1,2-a]pyridine 656239-69-9P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-71-3P, 7-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 656239-72-4P, 8-Methyl-3-[2-[4-(2-bromoethoxy)phenyl]pyridin-4-yl]-2-(6-methylpyridin-2-yl)imidazo[1,2-a]pyridine 657398-86-2P, 3-[2-[4-(2-Bromoethoxy)phenyl]pyridin-4-yl]-2-(3-chlorophenyl)imidazo[1,2-a]pyridine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders)


RN 656239-54-2 CAPLUS
 CN Benzaldehyde, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-

pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-55-3 CAPLUS

CN Benzaldehyde, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-56-4 CAPLUS

CN Benzaldehyde, 4-[4-[2-(3-chloro-4-fluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-57-5 CAPLUS

CN Benzaldehyde, 4-[4-[2-(3,4-difluorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-58-6 CAPLUS

CN Benzaldehyde, 4-[4-[2-(6-chloro-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-59-7 CAPLUS

CN Benzaldehyde, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-60-0 CAPLUS

CN Benzaldehyde, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-61-1 CAPLUS

CN Benzoic acid, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-62-2 CAPLUS

CN Phenol, 4-[4-[2-(2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-63-3 CAPLUS

CN Phenol, 4-[4-[2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-64-4 CAPLUS

CN Phenol, 4-[4-[2-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-65-5 CAPLUS

CN Phenol, 4-[4-[8-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-66-6 CAPLUS

CN Phenol, 4-[4-[7-methyl-2-(6-methyl-2-pyridinyl)imidazo[1,2-a]pyridin-3-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)




RN 656239-67-7 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-(4-bromophenyl)-4-pyridinyl]-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 656239-68-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 656239-69-9 CAPLUS

CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 656239-71-3 CAPLUS


CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-7-methyl-2-(6-methyl-2-pyridinyl)-
(9CI) (CA INDEX NAME)



RN 656239-72-4 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-8-methyl-2-(6-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 657398-86-2 CAPLUS
 CN Imidazo[1,2-a]pyridine, 3-[2-[4-(2-bromoethoxy)phenyl]-4-pyridinyl]-2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:07:59 ON 26 DEC 2006)

FILE 'REGISTRY' ENTERED AT 09:08:50 ON 26 DEC 2006

L1 STRUCTURE UPLOADED
 L2 2 S L1
 L3 66 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:09:26 ON 26 DEC 2006

L4 2 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.60	178.96

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.50	-1.50

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 09:11:04 ON 26 DEC 2006